Skip to main content

Table 2 Clinical outcomes during follow-up periods between patients with and without AOI

From: Clinical significance and long-term prognosis of ulcerative colitis patients with appendiceal orifice inflammation

Variables

AOI positive

(n = 98)

AOI negative

(n = 278)

p value

Maximal extent, no. (%)

0.699

Proctitis, no. (%)

39 (39.8)

115 (41.4)

 

Left-sided colitis, no. (%)

29 (29.6)

84 (30.2)

 

Extensive colitis, no. (%)

30 (30.6)

79 (28.4)

 

Proximal extension, no. (%)

24 (24.5)

50 (18.0)

0.184

Mayo endoscopic score at the last endoscopy

0.516

0–1, no. (%)

73 (74.5)

196 (70.5)

 

2–3, no. (%)

25 (25.5)

82 (29.5)

 

Histories of medications

High dose 5-ASA, no (%)

13 (13.3)

69 (24.8)

0.016

Corticosteroid, no. (%)

53 (54.1)

150 (54.0)

1.000

Azathioprine/6-MP, no. (%)

27 (27.6)

86 (30.9)

0.609

Anti-TNF agents, no. (%)

2 (2.0)

17 (6.1)

0.177

Colectomy, no. (%)

0 (0.0)

2 (0.7)

1.000

UC-related hospitalization, no. (%)

25 (25.5)

75 (27.0)

0.894

Relapse during follow-up periods, no. (%)

44 (44.9)

108 (38.8)

0.338

Follow-up duration, months, median (range)

56.5 (1-186)

52.0 (1-245)

0.285

  1. P value < 0.05 was regarded as statistically significant and is designated in bold
  2. AOI appendiceal orifice inflammation, 5-ASA 5-aminosalicylic acid, MP mercaptopurine, TNF tumor necrosis factor, UC ulcerative colitis, SD standard deviation